Cargando…
Efficacy and Cerebrospinal Fluid Rhinorrhea after Cabergoline Treatment in Patients with Bioactive Macroprolactinoma
SIMPLE SUMMARY: Predicting dopamine agonist resistance in patients with macroprolactinoma is essential for clinicians to prevent treatment failure and subsequent complications such as medication–induced cerebrospinal fluid (CSF) rhinorrhea. In this retrospective cross-sectional study that included 1...
Autores principales: | Kim, Hae-Kyung, Hong, Jae-Won, Moon, Ju-Hyung, Ahn, Sung-Soo, Kim, Eui-Hyun, Lee, Seung-Koo, Lee, Eun-Jig, Park, Yae-Won, Ku, Cheol-Ryong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582509/ https://www.ncbi.nlm.nih.gov/pubmed/34771538 http://dx.doi.org/10.3390/cancers13215374 |
Ejemplares similares
-
Early Prediction of Long-Term Response to Cabergoline in Patients with Macroprolactinomas
por: Lee, Youngki, et al.
Publicado: (2014) -
Cabergoline-Induced Pneumocephalus Following Treatment for Giant Invasive Macroprolactinoma Presenting With Spontaneous Cerebrospinal Fluid Rhinorrhea
por: Elabd, Souha S, et al.
Publicado: (2018) -
SUN-446 Association between Prolactin Level and Tumor Size Reduction at 3 Months after Cabergoline Treatment in Patients with Macroprolactinoma
por: Kim, Daham, et al.
Publicado: (2019) -
Bromocriptine or cabergoline-induced cerebrospinal fluid rhinorrhea: A life-threatening complication during management of prolactinoma
por: Singh, Pratibha, et al.
Publicado: (2011) -
Cerebrospinal fluid rhinorrhea
por: Mohanty, Aaron
Publicado: (2016)